沙特阿拉伯药品的外部参考定价政策:政策制定和方法论考虑
Fatimah Al Hussain1, Mona Almaghrabi1, Mohammed Al-Owairdhi1
1Pricing and Pharmacoeconomics Department, Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia.
Value in health regional issues
|March 13, 2026
概括
沙特阿拉伯通过根据社会经济因素,卫生系统和定价来选择可比的国家来完善其外部参考定价 (ERP) 政策. 这种简化流程减少了复杂性和吸引力,为全球药品定价策略提供了洞察力.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 国际定价 国际定价
背景情况:
- 外部参考定价 (ERP) 是药品价格监管的一个关键政策工具.
- 沙特阿拉伯试图优化其国家ERP政策,以与国际最佳实践和国家卫生需求保持一致.
研究的目的:
- 记录沙特阿拉伯在制定其外部参考定价 (ERP) 政策方面的经验.
- 详细说明ERP中使用的参考国家篮子的选择过程.
主要方法:
- 一项系统的文献审查确定了ERP政策制定和国家选择的标准.
- 沙特国家ERP政策根据文献发现,利益相关者的意见和国家卫生优先事项进行了调整.
- 使用精细的方法来选择一个可比的参考国家的篮子.
主要成果:
- 制定ERP政策的关键标准包括社会经济条件,卫生系统的强度,定价政策和地理接近.
- 沙特阿拉伯的参考国家篮子在2021年至2022年间从30个国家演变为16个可比的国家.
- 经过修订的ERP系统显示,程序复杂性降低,结果变化率降低.
结论:
- 沙特阿拉伯的ERP政策修订导致了更少的上诉和更简化的流程.
- 沙特的经验为其他国家实施或完善ERP政策提供了宝贵的见解.
- 本研究有助于了解ERP政策设计对药品价格和可访问性的影响.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235
Drug Products: Biologics, Biosimilars and Interchangeables
336
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
336
Pharmaceutical Equivalents
247
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
247
Bioequivalence of Drugs: Drugs with Multiple Indications
204
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
204
Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Drug Nomenclature
3.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.6K


